Chronic lymphocytic leukaemia: the role of T cells in a B cell disease.
Br J Haematol
; 186(2): 220-233, 2019 07.
Article
en En
| MEDLINE
| ID: mdl-30945268
ABSTRACT
Chronic lymphocytic leukaemia (CLL) has long been thought to be an immunosuppressive disease and abnormalities in T-cell subset distribution and function have been observed in many studies. However, the role of T cells (if any) in disease progression remains unclear and has not been directly studied. This has changed with the advent of new therapies, such as chimeric antigen receptor-T cells, which actively use retargeted patient-derived T cells as "living drugs" for CLL. However complete responses are relatively low (~26%) and recent studies have suggested the differentiation status of patient T cells before therapy may influence efficacy. Non-chemotherapeutic drugs, such as idelalisib and ibrutinib, also have an impact on T cell populations in CLL patients. This review will highlight what is known about T cells in CLL during disease progression and after treatment, and discuss the prospects of using T cells as predictive biomarkers for immune status and response to therapy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Purinas
/
Pirazoles
/
Pirimidinas
/
Linfocitos B
/
Leucemia Linfocítica Crónica de Células B
/
Inmunoterapia Adoptiva
/
Subgrupos de Linfocitos T
/
Quinazolinonas
Límite:
Humans
Idioma:
En
Revista:
Br J Haematol
Año:
2019
Tipo del documento:
Article
País de afiliación:
Reino Unido